PHAR logo

Pharming Group NV (PHAR) Company Overview

Profile

Full Name:

Pharming Group N.V.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

December 23, 2020

Indexes:

Not included

Website:

http://www.pharming.com

Description:

PHAR (Pharming Group NV) is a biotechnology company that develops innovative therapies for rare genetic diseases. They focus on producing treatments using recombinant DNA technology, aiming to improve the lives of patients with unmet medical needs. Their main product is for a condition called hereditary angioedema.

Key Details

Price

$8.70

Market Cap

$590.22 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$245.32 M(+19.30% YoY)

Annual EPS

-$0.16(-184.21% YoY)

PE Ratio

-

Annual ROE

-4.98%

Annual Debt To Equity

0.63

Beta

0.05

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Oct 24, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 17, 24 HC Wainwright & Co.
Buy
Dec 16, 24 HC Wainwright & Co.
Buy
Dec 11, 24 HC Wainwright & Co.
Buy
Dec 9, 24 Jefferies
Buy
Oct 28, 24 Oppenheimer
Outperform
Oct 24, 24 HC Wainwright & Co.
Buy
Oct 15, 24 HC Wainwright & Co.
Buy
Oct 10, 24 HC Wainwright & Co.
Buy
Sep 26, 24 HC Wainwright & Co.
Buy
Aug 1, 24 HC Wainwright & Co.
Buy

Screeners with PHAR included

Growing Shares Outstanding
Most recommended stocks
Best performing stocks last 3 months
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
Stocks with low beta
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$8.70
PHAR price is $8.70

Price All-time High

$16.70
PHAR price is currently -47.90% below its historical high of $16.70

Price Analysts Target

$30.00
PHAR price is currently -71.00% lower than the consensus analysts' forecast

Price Today Change

+2.72%
PHAR price is up +2.72% today

Price YTD Change

-13.55%
PHAR price is down -13.55% since January 1st

Price 3-Year Change

+4.32%
PHAR price is up +4.32% over the past 3 years

Market cap

Market Cap

$590.22 M
PHAR market capitalization is $590.22 million

Market Cap 3-Year Change

+9.09%
PHAR market capitalization is up +9.09% over the past 3 years

Market Cap All-time High

$1.07 B
PHAR market capitalization is currently -44.61% below its historical high of $1.07 billion

Market Cap Sector Rank

70.21%
PHAR market capitalization is higher than 70.21% of companies in Healthcare sector

Technical

Beta

0.05
PHAR beta is 0.05

200-day SMA

$8.48
PHAR price is currently +2.58% above its 200-day simple moving average

14-day RSI

53.65
PHAR 14-day relative strength index is 53.65

30-day Relative Volume

1.83
PHAR 30-day relative volume is 1.83

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$245.32 M
PHAR annual revenue is $245.32 million

Annual Revenue Analysts Estimate

$270.96 M
PHAR annual revenue is currently -9.46% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+19.3%
PHAR annual revenue is up +19.3% year-on-year

Annual Revenue Sector Rank

67.36%
PHAR annual revenue is higher than 67.36% of companies in Healthcare sector

Profit

Annual Gross Profit

$220.10 M
PHAR annual gross profit is $220.10 million

Annual Gross Margin

89.72%
PHAR annual gross profit margin is 89.72%

Annual Operating Profit

-$22.00 M
PHAR annual operating income is -$22.00 million

Annual Operating Margin

-8.97%
PHAR annual operating profit margin is -8.97%

Annual Net Income

-$10.55 M
PHAR annual net profit is -$10.55 million

Annual Net Margin

-4.30%
PHAR annual net profit margin is -4.30%

EPS

Annual EPS

-$0.16
PHAR annual earnings per share is -$0.16

Annual EPS Analysts Estimate

-$0.01
PHAR annual earnings per share is currently +1180.00% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

-184.21%
PHAR annual earnings per share is down -184.21% year-on-year

Annual EPS Sector Rank

78.8%
PHAR annual earnings per share is higher than 78.8% of companies in Healthcare sector

ROA & ROE

Annual ROA

-2.37%
PHAR annual return on assets is -2.37%

Annual ROE

-4.98%
PHAR annual return on equity is -4.98%

EBIT & EBITDA

Annual EBIT

-$6.05 M
PHAR annual earnings before interest & taxes is -$6.05 million

Annual EBITDA

$9.88 M
PHAR annual EBITDA is $9.88 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
PHAR price to earnings ratio value is unknown

PE Ratio Sector Rank

-
PHAR price to earnings ratio is unknown

PB Ratio

PB Ratio

2.61
PHAR price to book ratio is 2.61

PB Ratio Sector Rank

67.08%
PHAR price to book ratio is higher than 67.08% of companies in Healthcare sector

PS Ratio

PS Ratio

2.07
PHAR price to sales ratio is 2.07

PS Ratio Sector Rank

40.13%
PHAR price to sales ratio is higher than 40.13% of companies in Healthcare sector

Enterprise value

Enterprise Value

$656.64 M
PHAR enterprise value is $656.64 million

Enterprise Value Sector Rank

71.01%
PHAR enterprise value is higher than 71.01% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

95.32
PHAR EV/EBITDA is 95.32

EV/EBITDA Sector Rank

98.23%
PHAR EV/EBITDA is higher than 98.23% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.06
PHAR annual current ratio is 4.06

Annual Quick Ratio

3.33
PHAR annual quick ratio is 3.33

Leverage

Annual Debt To Equity

0.63
PHAR annual debt to equity ratio is 0.63

Annual Interest Coverage Ratio

-1.01
PHAR annual interest coverage ratio is -1.01

Risk & Stability

Piotroski F-Score

5
PHAR piotroski f-score is 5

Altman Z-Score

1.75
PHAR altman z-score is 1.75

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$462.85 M
PHAR annual total assets is $462.85 million

Annual Non Current Assets

$146.51 M
PHAR annual long term assets is $146.51 million

Annual Current Assets

$316.34 M
PHAR annual total current assets is $316.34 million

Annual Cash & Cash Equivalents

$61.74 M
PHAR annual cash & cash equivalents is $61.74 million

Equity

Annual Book Value

$218.78 M
PHAR annual book value is $218.78 million

Annual Working Capital

$238.37 M
PHAR annual working capital is $238.37 million

Liabilities

Annual Total Liabilities

$244.07 M
PHAR annual total liabilities is $244.07 million

Annual Total Long Term Liabilities

$166.10 M
PHAR annual total long term liabilities is $166.10 million

Annual Current Liabilities

$77.97 M
PHAR annual total current liabilities is $77.97 million

Annual Accounts Payable

$16.02 M
PHAR annual accounts payable is $16.02 million

Debt

Annual Total Debt

$171.54 M
PHAR annual total debt is $171.54 million

Annual Total Debt 1-Year Change

+2.91%
PHAR annual total debt is up +2.91% year-on-year

Annual Long Term Debt

$166.10 M
PHAR annual long term debt is $166.10 million

Annual Short Term Debt

$5.44 M
PHAR annual short term debt is $5.44 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$267.32 M
PHAR annual total expenses is $267.32 million

Annual Operating Expenses

$242.11 M
PHAR annual total operating expenses is $242.11 million

Annual Cost Of Goods Sold

$25.21 M
PHAR annual cost of goods sold is $25.21 million

Annual SGA

$87.50 M
PHAR annual SGA is $87.50 million

Annual D&A

$15.93 M
PHAR annual depreciation & amortization is $15.93 million

Annual Interest Expense

$5.96 M
PHAR annual interest expense is $5.96 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$17.30 M
PHAR annual cash flow from operations is -$17.30 million

Annual CFO 1-Year Change

-177.04%
PHAR annual cash flow from operations is down -177.04% year-on-year

Annual CFI

-$129.39 M
PHAR annual cash flow from investing activities is -$129.39 million

Annual CFI 1-Year Change

-2530.73%
PHAR annual cash flow from investing activities is down -2530.73% year-on-year

Annual CFF

-$1.04 M
PHAR annual cash flow from financing activities is -$1.04 million

Annual CFF 1-Year Change

+79.14%
PHAR annual cash flow from financing activities is up +79.14% year-on-year

Free CashFlow

Annual FCF

-$18.77 M
PHAR annual free cash flow is -$18.77 million

Annual FCF 1-Year Change

-191.63%
PHAR annual free cash flow is down -191.63% year-on-year

CAPEX

Annual CAPEX

$1.46 M
PHAR annual capital expenditures is $1.46 million

Annual CAPEX 1-Year Change

-25.95%
PHAR annual capital expenditures is down -25.95% year-on-year

Institutional Ownership

Similar stocks

TMCI logo
Treace Medical Concepts (TMCI)
Auna SA (AUNA)
IMNM logo
Immunome (IMNM)
SLP logo
Simulations Plus (SLP)
ACCD logo
Accolade (ACCD)
KURA logo
Kura Oncology (KURA)
CTKB logo
Cytek Biosciences (CTKB)
KALV logo
KalVista Pharmaceuticals (KALV)
DNTH logo
Dianthus Therapeutics (DNTH)

FAQ

  • What is the ticker symbol for Pharming Group NV?
  • Does Pharming Group NV pay dividends?
  • What sector is Pharming Group NV in?
  • What industry is Pharming Group NV in?
  • What country is Pharming Group NV based in?
  • When did Pharming Group NV go public?
  • Is Pharming Group NV in the S&P 500?
  • Is Pharming Group NV in the NASDAQ 100?
  • Is Pharming Group NV in the Dow Jones?
  • When was Pharming Group NV's last earnings report?
  • When does Pharming Group NV report earnings?
  • Should I buy Pharming Group NV stock now?

What is the ticker symbol for Pharming Group NV?

The ticker symbol for Pharming Group NV is NASDAQ:PHAR

Does Pharming Group NV pay dividends?

No, Pharming Group NV does not pay dividends

What sector is Pharming Group NV in?

Pharming Group NV is in the Healthcare sector

What industry is Pharming Group NV in?

Pharming Group NV is in the Biotechnology industry

What country is Pharming Group NV based in?

Pharming Group NV is headquartered in Netherlands

When did Pharming Group NV go public?

Pharming Group NV's initial public offering (IPO) was on December 23, 2020

Is Pharming Group NV in the S&P 500?

No, Pharming Group NV is not included in the S&P 500 index

Is Pharming Group NV in the NASDAQ 100?

No, Pharming Group NV is not included in the NASDAQ 100 index

Is Pharming Group NV in the Dow Jones?

No, Pharming Group NV is not included in the Dow Jones index

When was Pharming Group NV's last earnings report?

Pharming Group NV's most recent earnings report was on Oct 24, 2024

When does Pharming Group NV report earnings?

The next expected earnings date for Pharming Group NV is Mar 14, 2025

Should I buy Pharming Group NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions